Celltrion announced that all three of its antibody-drug conjugate (ADC) candidates have received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation allows the company to closely collaborate with the FDA on development and approval strategies, aiming to expedite global commercialization.
The FDA's Fast Track program is designed to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. With this designation, Celltrion can engage in close consultations with the FDA throughout the clinical development process, receiving active support in clinical design and approval strategy.
On August 13, Celltrion revealed that its ADC candidate 'CT-P73' has been designated as a Fast Track target by the FDA. This means that all three ADC candidates currently undergoing Phase 1 trials (CT-P70, CT-P71, CT-P73) have received Fast Track status.
The Fast Track designation for CT-P73 specifically targets treatment indications for patients with recurrent and metastatic cervical cancer who have a history of platinum-based chemotherapy (PBC).
Celltrion is conducting Phase 1 trials for CT-P70, CT-P71, and CT-P73, which target c-MET, Nectin-4, and tissue factors, respectively. CT-P70 received Fast Track designation from the FDA in December of last year, while CT-P71 was designated in April.
Celltrion plans to directly manage the development and global commercialization of the most competitive candidates among the three ADCs, aiming to cultivate them as key drivers of long-term new drug revenue. For candidates that are favorable for strategic partnerships, the company intends to pursue licensing agreements to explore early monetization opportunities through royalties and milestone payments.
A Celltrion representative stated, "We will strategically choose between in-house development and commercialization or technology transfer for each candidate based on a thorough evaluation of clinical data and market potential, thereby enhancing both the long-term growth value and early monetization prospects of our new drugs."
Celltrion aims to complete Phase 1 Part 1 trials for two of the three ADC candidates by the end of this year and plans to sequentially announce topline results starting in the first half of next year. The company also intends to rapidly advance into Part 2 for dose optimization. The fastest-developing candidate, CT-P70, is targeting a Part 2 entry by March of next year.
Additionally, Celltrion plans to apply for Fast Track designation for its multi-antibody candidate CT-P72 within this year. Following the ADCs, the company aims to expand its new drug pipeline with multi-antibodies and strengthen the long-term growth foundation of its new drug sector by linking development-stage achievements with commercialization strategies.
The FDA's Fast Track program is designed to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. With this designation, Celltrion can engage in close consultations with the FDA throughout the clinical development process, receiving active support in clinical design and approval strategy.
On August 13, Celltrion revealed that its ADC candidate 'CT-P73' has been designated as a Fast Track target by the FDA. This means that all three ADC candidates currently undergoing Phase 1 trials (CT-P70, CT-P71, CT-P73) have received Fast Track status.
The Fast Track designation for CT-P73 specifically targets treatment indications for patients with recurrent and metastatic cervical cancer who have a history of platinum-based chemotherapy (PBC).
Celltrion is conducting Phase 1 trials for CT-P70, CT-P71, and CT-P73, which target c-MET, Nectin-4, and tissue factors, respectively. CT-P70 received Fast Track designation from the FDA in December of last year, while CT-P71 was designated in April.
Celltrion plans to directly manage the development and global commercialization of the most competitive candidates among the three ADCs, aiming to cultivate them as key drivers of long-term new drug revenue. For candidates that are favorable for strategic partnerships, the company intends to pursue licensing agreements to explore early monetization opportunities through royalties and milestone payments.
A Celltrion representative stated, "We will strategically choose between in-house development and commercialization or technology transfer for each candidate based on a thorough evaluation of clinical data and market potential, thereby enhancing both the long-term growth value and early monetization prospects of our new drugs."
Celltrion aims to complete Phase 1 Part 1 trials for two of the three ADC candidates by the end of this year and plans to sequentially announce topline results starting in the first half of next year. The company also intends to rapidly advance into Part 2 for dose optimization. The fastest-developing candidate, CT-P70, is targeting a Part 2 entry by March of next year.
Additionally, Celltrion plans to apply for Fast Track designation for its multi-antibody candidate CT-P72 within this year. Following the ADCs, the company aims to expand its new drug pipeline with multi-antibodies and strengthen the long-term growth foundation of its new drug sector by linking development-stage achievements with commercialization strategies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.